Over the past century, the pharmaceutical industry has consolidated itself as one of the most influential sectors of the global economy, exerting impacts that extend beyond production and reach scientific research, clinical practice, and health-related decision-making processes. Beyond the scientific and technological advances that have driven its expansion, critical scholarship has emphasized the adoption of structural mechanisms of corporate influence capable of shaping public policies, research agendas, and therapeutic guidance. This scientific report analyzes, in a concise and accessible manner, three central dimensions of this phenomenon: the influence of the pharmaceutical industry on regulatory and oversight agencies, patient organizations, and the development of clinical guidelines. Drawing on empirical evidence, case studies, and data from the international literature, the analysis examines the recurrence of financial conflicts of interest in regulatory committees, the systematic funding of patient associations, and the financial ties between authors of medical guidelines and pharmaceutical companies. The evidence presented demonstrates that these practices do not represent isolated episodes, but rather institutionalized arrangements with cumulative effects on regulatory decisions, public narratives surrounding disease, and global prescribing patterns. By rendering these mechanisms visible, the report contributes to ongoing public debate on transparency, health governance, and the contemporary challenges posed by a sector characterized by high profitability, power asymmetries, and expanding influence over health systems.